Introduction {#Sec1}
============

Mebendazole (MBZ), a drug commonly prescribed for various forms of helminthic diseases has demonstrated anticancer activity in several in vitro and in vivo model systems \[[@CR1]--[@CR11]\]. In the clinical setting MBZ has also induced tumour responses in therapy-resistant patients with adrenocortical and colorectal cancer \[[@CR12], [@CR13]\].

The primary anticancer mechanism of MBZ has been attributed to its ability to target and inhibit tubulin polymerization in tumour cells \[[@CR3], [@CR4]\]. However, other mechanisms, such as angiogenesis inhibition \[[@CR6], [@CR9]\], apoptosis induction \[[@CR2], [@CR8]\] and inhibition of the Hedgehog signalling pathway \[[@CR14]\] have been proposed. Moreover, MBZ has also been shown to potently bind to several protein kinases involved in oncogenic signaling \[[@CR7]\].

Recently, we showed that MBZ induce a pro-inflammatory tumour-suppressive M1 phenotype in THP-1 monocytes and macrophages which could potentially explain tumour cell killing \[[@CR15]\]. We also recently demonstrated that MBZ potentiate the anti-cancer activity of CD3/IL2 activated peripheral blood mononuclear cells (PBMCs) and that this effect was attenuated by removal of CD14+ myeloid cells \[[@CR16]\]. Hence, MBZ is seemingly an interesting small molecule drug to tilt the M2 rich tumour microenvironment in favour of M1 macrophage differentiation, which in turn may induce anti-tumour immunity.

In the present study, we investigated the possible role of protein kinases for the immune modulating properties of MBZ in THP-1 monocytes and macrophages. The results show that DYRK1B inhibition could, at least partly, mimic the immune responses induced by MBZ and could be part of the mechanism of action for its macrophage M1 polarisation.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Materials {#Sec4}

MBZ, AZ191, lipopolysaccharide (LPS), interferon gamma (IFNγ), interleukin-13 (IL13), phorbol-12-myristate-13-acetate (PMA) and interleukin-4 (IL4) were purchased from Sigma Aldrich (Sigma, St. Louis, MO, USA). The compounds were stored as 10 mM stock solutions in dimethylsulfoxide (DMSO, Honeywell, Morris Plains, NJ, USA) or sterile water and further diluted with culture medium (see below).

### Cell culture {#Sec5}

Cell culture was performed as previously described \[[@CR15]\]. Monocytoid THP-1 cells were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, [l]{.smallcaps}-glutamine (2 mM), penicillin/streptomycin (100 U/100 µg/mL) and 0.05 mM 2-mercaptoethanol (Sigma). The cell line was cultured at 37 °C in a humidified atmosphere with 5% CO~2~. For the differentiation and polarisation of THP-1 cells to macrophages, PMA (97.2 nM), IFNγ (20 ng/mL), LPS (100 ng/mL), IL4 (20 ng/mL) and 20 ng/mL IL13 (final concentrations) were used according to an established protocol with minor modifications \[[@CR17]\]. PMA was added to THP-1 cells seeded into wells of a 12-well plate (Corning). After 30 h incubation, LPS/IFNγ (M1), IL4/IL13 (M2), DMSO (control), AZ191 and MBZ were added to separate wells. After an additional 18 h incubation time the medium was collected and analysed. In some experiments cells were lysed and analysed for phosphoprotein activity.

### Protein kinase assays {#Sec6}

The binding affinities of MBZ were tested in a binding assay (DiscoverX, CA) against DYRK1B kinase tagged with DNA. Compounds that bind the kinase active site and directly or indirectly prevent kinase binding to an immobilised ligand, will reduce the amount of kinase captured on solid support. Conversely, test molecules that do not bind the kinase have no effect on the amount of kinase captured on the solid support. Binding constants were determined with this method using 11-point threefold serial dilutions of the compound. Curves were fitted using a non-linear least square t with the Levenberg--Marquardt algorithm \[[@CR18]\]. Inhibition of DYRK1B activity was performed by Reaction labs, USA. Briefly, compounds were tested in 10-dose IC~50~ mode with threefold serial dilution starting at 10 μM and reactions were carried out at 10 μM ATP. Data are presented as % enzyme activity (relative to DMSO controls).

### Measurement of M1 and M2 surface marker expression {#Sec7}

Surface markers was measured as previously described \[[@CR15]\]. THP-1 cells were incubated for 24 h with PMA, DMSO and AZ191. The cells were subsequently washed with cell culture media and incubated for an additional 24 h. Cells were then detached and mixed with the conjugated antibodies CD80-PC7 and CD163-PE (Beckman Coulter, Indianapolis, IN, USA). After 15 min, cells were washed with PBS (Sigma) and subsequently analysed on a Navios flow cytometer (Beckman Coulter) using the Kaluza software (Beckman Coulter).

### Measurement of cytokines and phosphoproteins {#Sec8}

Cytokines and phosphoproteins were measured using the Luminex/MAGPIX system and commercially available kits (Biorad, Hercules, CA) and were performed as described previously \[[@CR15]\] and according to the instructions from the manufacturer. Briefly, for the cytokine assay supernatant samples were incubated with beads, detection antibody and streptavidin-PE. The fluorescence was subsequently measured using the MAGPIX instrument. For the phosphoprotein assay cell lysates were used and protein concentrations were determined using a Micro-BCA method (ThermoFischer Scientific, Waltham, MA, USA) to obtain equal amounts of samples in the assay.

### Statistical analysis {#Sec9}

Statistical analysis was performed using the Students t-test module in GraphPadPrism (GraphPad Software, San Diego, CA).

Results and discussion {#Sec10}
----------------------

We previously showed that MBZ selectively and potently binds to several protein kinases \[[@CR7]\]. When repeating and extending the initial kinase screen we noted that MBZ affected the dual specificity tyrosine phosphorylation-regulated kinase 1B (DYRK1B). In concentration--response experiment for binding affinity to DYRK1B, MBZ showed a kD of 7 nM and potently inhibited the kinase activity, with an IC~50~ of 360 nM (Fig. [1](#Fig1){ref-type="fig"}a, b). This should be compared with binding data (kD) for other hit kinases from the screening of the Scanedge and Kinomescan 456 from DiscoverX (Fig. [1](#Fig1){ref-type="fig"}c). The Kd of 7 nM for DYRK1B clearly stands out being considerably lower than for other kinases including ABL, BRAF and DYRK1A (Fig. [1](#Fig1){ref-type="fig"}c). The 7 nM Kd for MBZ binding to DYRK1B is a low concentration, compared with MBZ inhibition of tubulin polymerisation, which requires concentrations exceeding 1 µM \[[@CR15]\]. These results are in accordance with validated results from the RepurposeVS, a drug repurposing computational platform \[[@CR19]\]. DYRK1B is a serine/threonine kinase that is widely expressed in various cells especially in nondividing cells such as myoblasts that exit the cellcycle to terminally differentiate. DYRK1B controls the cellular change from a noncycling G0 state to S phase and also diminish oxidative stress by reducing intracellular levels of reactive oxygen species (ROS) \[[@CR20]\]. Furthermore, DYRK1B is overexpressed in a subset of cancers and maintains cellular quiescence which increases cell survival in e.g. ovarian-, pancreatic-, and colon cancer \[[@CR21]--[@CR23]\].Fig. 1Inhibition of binding (**a**) and enzyme activity (**b**) of DYRK1B by MBZ. Measurements was performed by DiscoverX and Reactionlabs as detailed in methods. The Kd measurement was repeated with identical results. In **c** Kd determinations for other kinases analysed in parallel are shown

Next we tested the effect of MBZ and the selective inhibitor of DYRK1B, AZ191 \[[@CR24]\], on cytokine release from THP-1 monocytes. AZ191 did not mimic the cytokine release profile induced by MBZ in untreated THP-1 monocytes (Fig. [2](#Fig2){ref-type="fig"}a, b) and only a small effect on IL1β secretion was noted when the cells were primed with LPS (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1). In contrast, MBZ at 10 µM strongly induced cytokine release in these cells and in lower concentrations (1 µM) the effect on IL1β secretion could be clearly potentiated by priming with LPS (Fig. [2](#Fig2){ref-type="fig"}a and Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).Fig. 2Cytokine release from monocytoid THP-1 cells in response to 24 h exposure to MBZ (**a**) and AZ191 (**b**). Corresponding cytokine release from PMA differentiated THP-1 macrophages in response to M1 stimuli LPS/IFNγ (**c**), M2 stimuli IL4/IL13 (**d**), MBZ 10 µM (**e**) and AZ191 10 µM (**f**) after 48 h of incubation (30 h PMA + 18 h with added stimuli and drugs). The results are expressed as relative fluorescence units (RFU) and presented as mean values ± standard deviation for duplicate measurements. Measurements was performed by a Luminex MAGPIX instrument and a multiplex kit from Biorad. The measurements of selected cytokines (IL1β and TNF) were repeated in 4 independent experiments with similar results. See "[Results](#Sec10){ref-type="sec"}" for details

In contrast, in THP-1 cells differentiated to macrophages by PMA, AZ191 induced a M1-like pro-inflammatory cytokine release pattern similar to MBZ and LPS/IFNγ (Fig. [2](#Fig2){ref-type="fig"}c--f). MBZ (Fig. [2](#Fig2){ref-type="fig"}e), LPS/IFNγ (Fig. [2](#Fig2){ref-type="fig"}c) and AZ191 (Fig. [2](#Fig2){ref-type="fig"}f) clearly increased both IL1β and TNF (tumour necrosis factor) and decreased VEGF (vascular endothelial growth factor) opposite to the effect of M2 inducing IL13/IL4 stimulation (Fig. [2](#Fig2){ref-type="fig"}d). In repeat experiments with IL1β and TNF the effect of AZ191 was statistically significant compared to DMSO control (P \< 0.01, n = 4, paired Students t-test). Moreover, AZ191 increased the expression of the M1 marker CD80 and decreased the M2 marker CD163 in the THP-1 macrophage model (Fig. [3](#Fig3){ref-type="fig"}a with the original flow cytometry histograms shown in Additional file [2](#MOESM2){ref-type="media"}: Fig. S2), corroborating previously published results for MBZ \[[@CR15]\].Fig. 3Flow cytometry analysis of CD80 and CD163 expression in response to 10 µM AZ191 (**a**) after 48 h of incubation. In **b** the effect of AZ191 and MBZ on ERK phosphoprotein activation in PMA differentiated THP-1 cells is shown. ERK activity was measured after 1 h exposure of the drugs. The results are expressed as relative fluorescence units (RFU) and presented as mean values ± standard deviation for duplicate measurements. See "[Methods](#Sec3){ref-type="sec"}" for details. Measurements were performed by a Luminex Magpix instrument and a ERK phosphoprotein kit from Biorad. A lysate of EGF-treated HEK293 cells provided in the kit served as positive control

The difference between THP-macrophages and THP-1 monocytes in response to AZ191 and MBZ is presently unexplained. Monocytoid THP-1 cells are often used as surrogate model for dendritic cells (DCs) in evaluation of allergen potential of small molecules \[[@CR25]--[@CR27]\]. MBZ-induced cytokine release in naive THP-1 cells is dominated by IL1β and IL8, a response considered to reflect maturation of immature DCs to active functional antigen-presenting DCs \[[@CR25], [@CR28]\]. Based on the expression profile for 13 gene markers for DC activation, the monocytic THP-1 cells significantly more closely resembled the human DC model compared to THP-1 differentiated macrophages \[[@CR25]\]. On the other hand, THP-1 macrophages have been reported to closely mimic the phenotype of human macrophages \[[@CR29]\]. Thus, these cellular models reflecting DCs and macrophages are different and this may also apply to signaling pathways.

One consequence of DYRK1B inhibition is ERK (extracellular signal-regulated kinase) activation and it has previously been shown that MBZ strongly induces ERK activation \[[@CR30]\]. Indeed, although less pronounced than for MBZ, AZ191 dose-dependently increased phospho-ERK activity in THP-1 macrophages (Fig. [3](#Fig3){ref-type="fig"}b). Previous studies have demonstrated that IL1β release require two signals. The first is provided by toll-like-receptor-mediated NF-kappaB activation whereas the second can be mediated by danger signals such as stimulation of ATP receptors or other stimuli including elevated ROS production or perturbation of lysosome integrity \[[@CR15]\]. In this study it was demonstrated that high dose MBZ (\> 3 µM) activated both signals, the first via TLR8 stimulation, whereas low concentrations (1 µM) only could activate the second one \[[@CR15]\]. From the data presented here one can speculate that ERK activation induced by MBZ and AZ191 might be the second signal in PMA differentiated THP-1 macrophages. However, it should be noted that the present results are only based on one cell line model only and the relevance to the human immune system remains to be established.

Monocytes and macrophages may express at least two different phenotypes which can be either pro-inflammatory (M1) or anti-inflammatory (M2) \[[@CR17], [@CR31], [@CR32]\]. The M1 monocytes/macrophages is characterised by tumor-suppressive properties such as production of cytokines that activate T-cells and can also induce direct cytotoxic anti-tumour effects. The M2 counterpart is the typical phenotype present in solid tumours and exert tumour-supporting functions such as immunosuppression and stimulation of angiogenesis \[[@CR17], [@CR31], [@CR32]\]. Small molecules that have the capability to shift the polarisation from M2 to M1 would thus be potentially interesting for cancer therapy. This type of drugs could also be fruitfully combined with other immunotherapy, such as checkpoint inhibitors or CAR T cells. If MBZ is such a drug will require further investigation.

Limitations {#Sec11}
===========

The work is restricted only to cell line models.

Additional files
================

 {#Sec12}

**Additional file 1: Fig. S1.** The effect of AZ191 and MBZ with and without LPS on IL-1 release in THP-1 monocytes is shown. **Additional file 2: Fig. S2.** Original flow cytometry histograms from Fig. [3](#Fig3){ref-type="fig"} is shown.
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